SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone to industry. These are excellent sources of funding aimed at promoting R&D activities of small businesses as well as collaborations with Academics. SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, […]
In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies. The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage […]
Assembling a budget for your grant is typically the last item to be addressed. Reason being that the figures you are suggesting must reflect the work you are proposing to complete. That said, simply stating the cost per item is hardly enough, and a properly constructed justification is mandatory and weighs heavily on approval of […]
NINDS has just issued a number of funding opportunities covering separately the development of biologics, small molecules and devices in a cooperative manner with the issuing institute (U-Mechanism). This serves a major paradigm shift in NINDS funding. Further, within the non-dilutive funding space one can find pockets of money in the billions of dollars directed […]
NIH alone awards roughly $5.8B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well. In this webinar in the series of summer educational webinars, FreeMind experts discuss key cancer related opportunities, […]
Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. In this presentation we will provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available […]
Every year NIH alone awards over $120,000,000 via R’-Mechanisms, among them the RO1 or R21. In order to maximize your funding potential all sources of funding must be considered including the less traditional sources. R21s aim to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas […]
The National Institute of Allergy and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA, etc. this is a funding force no one in the field can afford to ignore. Date: Wednesday, July 16 Time: 12:00 – 1:00 PM, EDT In this first webinar in the […]
Weekly Online Educational Webinars – July 2nd – August 27th, 2014 FreeMind’s knowledgeable team of expert grant writers share their wisdom on how to maximize chances for award. Participation is FREE of Charge, Registration is Required Date Title July 16th Biodefense and Infectious Diseases Non-dilutive Funding July 23rd RO1 and R21s for Companies July 30th […]
The FreeMind Group and CONNECT are pleased to invite you to a full day of non-dilutive funding activities on June 23rd at the Procopio Law offices – 525 B Street, Suite 2200 – Participation is FREE of charge Seating is limited, so please register in advance to reserve AGENDA Non-dilutive Funding During the BIO International […]